Merck's Welireg receives FDA nod for expanded use with Lenvima in kidney cancer

Merck announced that its drug Welireg has received FDA approval for use together with Eisai's Lenvima in patients with advanced renal cell carcinoma.

The clearance broadens the indication, allowing the combination to be prescribed to a larger group of kidney-cancer patients than previously approved.

Clinical data supporting the decision showed that the regimen improves outcomes for the targeted population.

The therapy will now be accessible to patients meeting the new criteria, representing a significant step for both companies.